{
    "clinical_study": {
        "@rank": "15140", 
        "arm_group": {
            "arm_group_label": "BR55", 
            "arm_group_type": "Experimental", 
            "description": "BR55, a new ultrasound contrast agent"
        }, 
        "brief_summary": {
            "textblock": "Pilot study to evaluate the sensitivity and specificity of BR55 targeting for prostate\n      cancer nodules with Gleason score greater than or equal to 7."
        }, 
        "brief_title": "A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, age between 50-70 years old\n\n          -  Increased PSA level >4 ng/mL\n\n          -  Known prostate cancer\n\n          -  Scheduled for prostatectomy not earlier than 3 days and not later than 30 days\n             following BR55 administration (with the exception of training cases where this\n             requirement is not applicable)\n\n          -  Provides written informed consent and willing to comply with protocol requirements\n\n        Exclusion Criteria:\n\n          -  Documented acute prostatitis or urinary tract infections\n\n          -  Known to suffer from stable angina pectoris and/or proven coronary disease, or have\n             symptoms suspicious of coronary disease\n\n          -  History of any clinically unstable cardiac condition including class III/IV cardiac\n             failure or right-to left shunts\n\n          -  Severe cardiac rhythm disorders within the last 7 days\n\n          -  Severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory\n             distress syndrome\n\n          -  Received a prostate biopsy procedure within 30 days before admission into the study\n\n          -  Determined by investigator to be clinically unsuitable for the study\n\n          -  Participating in a concurrent clinical trial or has participated in another clinical\n             trial with an investigational compound within the past 30 days"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142608", 
            "org_study_id": "BR55-105"
        }, 
        "intervention": {
            "arm_group_label": "BR55", 
            "intervention_name": "BR55", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Prostate cancer", 
            "Ultrasound Imaging"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94306"
                }, 
                "name": "Stanford University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2", 
        "overall_contact": {
            "email": "annSharon.jannu@diag.bracco.com", 
            "last_name": "Ann Jannu", 
            "phone": "609-514-2554"
        }, 
        "overall_official": [
            {
                "affiliation": "Bracco Diagnostics, Inc", 
                "last_name": "Maria Luigia Storto, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Stanford University", 
                "last_name": "Juergen Willmann, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Using a visual score of ultrasound molecular imaging (USMI) when compared to histopathology results, the sensitivity and specificity of BR55 targeting for prostate cancer nodules with a gleason score that is greater than or equal to 7 will be an outcome measure assessed in this study", 
            "measure": "Sensitivity and specificity of BR55", 
            "safety_issue": "No", 
            "time_frame": "Within 30 minutes after administration of BR55"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142608"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bracco Diagnostics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bracco Diagnostics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}